Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 414

1.

Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S483-S488. No abstract available.

2.

The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S475-S482. No abstract available.

3.

Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S468-S474. No abstract available.

4.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2018 Oct 17. doi: 10.1093/hmg/ddy361. [Epub ahead of print]

PMID:
30335132
5.

Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis.

Salzer HJF, Prattes J, Flick H, Reimann M, Heyckendorf J, Kalsdorf B, Obersteiner S, Gaede KI, Herzmann C, Johnson GL, Lange C, Hoenigl M.

Front Microbiol. 2018 Oct 2;9:2223. doi: 10.3389/fmicb.2018.02223. eCollection 2018.

6.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium .

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

PMID:
29982664
7.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

8.

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM.

SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9.

PMID:
29742358
9.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

10.

Unexplored therapeutic opportunities in the human genome.

Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, Ma'ayan A, Malovannaya A, Mani S, Mathias SL, McManus MT, Meehan TF, von Mering C, Muthas D, Nguyen DT, Overington JP, Papadatos G, Qin J, Reich C, Roth BL, Schürer SC, Simeonov A, Sklar LA, Southall N, Tomita S, Tudose I, Ursu O, Vidovic D, Waller A, Westergaard D, Yang JJ, Zahoránszky-Köhalmi G.

Nat Rev Drug Discov. 2018 May;17(5):377. doi: 10.1038/nrd.2018.52. Epub 2018 Mar 23.

PMID:
29567993
11.

Unexplored therapeutic opportunities in the human genome.

Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, Ma'ayan A, Malovannaya A, Mani S, Mathias SL, McManus MT, Meehan TF, von Mering C, Muthas D, Nguyen DT, Overington JP, Papadatos G, Qin J, Reich C, Roth BL, Schürer SC, Simeonov A, Sklar LA, Southall N, Tomita S, Tudose I, Ursu O, Vidovic D, Waller A, Westergaard D, Yang JJ, Zahoránszky-Köhalmi G.

Nat Rev Drug Discov. 2018 May;17(5):317-332. doi: 10.1038/nrd.2018.14. Epub 2018 Mar 23. Review. Erratum in: Nat Rev Drug Discov. 2018 Mar 23;:.

PMID:
29472638
12.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

PMID:
29472518
13.

Evaluation of the new AspID polymerase chain reaction assay for detection of Aspergillus species: A pilot study.

Prattes J, Hoenigl M, Zinke SE, Heldt S, Eigl S, Johnson GL, Bustin S, Stelzl E, Kessler HH.

Mycoses. 2018 Jun;61(6):355-359. doi: 10.1111/myc.12757. Epub 2018 Mar 23.

PMID:
29460450
14.

Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).

Ahmad S, St Hilaire VR, Dandepally SR, Johnson GL, Williams AL, Scott JE.

Biochem Biophys Res Commun. 2018 Jan 29;496(1):205-211. doi: 10.1016/j.bbrc.2018.01.027. Epub 2018 Jan 5.

PMID:
29309787
15.

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.

Bevill SM, Zawistowski JS, Johnson GL.

Mol Cell Oncol. 2017 Mar 31;4(6):e1300622. doi: 10.1080/23723556.2017.1300622. eCollection 2017.

16.

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.

Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, Bear JE.

Cancer Res. 2018 Jan 15;78(2):542-557. doi: 10.1158/0008-5472.CAN-17-1653. Epub 2017 Nov 27.

PMID:
29180473
17.

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling.

Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, Major MB.

Mol Cancer Res. 2018 Feb;16(2):333-344. doi: 10.1158/1541-7786.MCR-17-0468. Epub 2017 Nov 13.

PMID:
29133594
18.

Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.

Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher WJ.

ChemMedChem. 2018 Jan 8;13(1):48-66. doi: 10.1002/cmdc.201700663. Epub 2017 Nov 27.

PMID:
29072804
19.

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.

Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC.

J Am Heart Assoc. 2017 Oct 19;6(10). pii: e006635. doi: 10.1161/JAHA.117.006635.

20.

Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.

Jensen BC, Parry TL, Huang W, Beak JY, Ilaiwy A, Bain JR, Newgard CB, Muehlbauer MJ, Patterson C, Johnson GL, Willis MS.

Br J Pharmacol. 2017 Dec;174(24):4797-4811. doi: 10.1111/bph.14062. Epub 2017 Nov 24.

PMID:
28977680
21.

Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.

Angus SP, Zawistowski JS, Johnson GL.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:209-229. doi: 10.1146/annurev-pharmtox-010617-052954. Epub 2017 Sep 15.

PMID:
28934561
22.

Pharmacologic targeting of drug-induced enhancers.

Zawistowski JS, Bevill SM, Johnson GL.

Oncoscience. 2017 Jun 22;4(5-6):43-44. doi: 10.18632/oncoscience.354. eCollection 2017 May. No abstract available.

23.

Ambulatory care pharmacy: Realizing the potential for patient access and operational excellence.

Almeter PJ, Johnson GL, Schwieterman PA, Grantz DA, Pasala PP.

Am J Health Syst Pharm. 2017 Jul 1;74(13):1013-1019. doi: 10.2146/ajhp160802. No abstract available.

PMID:
28645999
24.

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo.

Jensen BC, Parry TL, Huang W, Ilaiwy A, Bain JR, Muehlbauer MJ, O'Neal SK, Patterson C, Johnson GL, Willis MS.

Metabolites. 2017 Jun 22;7(3). pii: E31. doi: 10.3390/metabo7030031.

25.

Assessing the Informed Consent Skills of Emergency Medicine Resident Physicians.

Binstadt ES, Curl ND, Nelson JG, Johnson GL, Hegarty CB, Knopp RK.

AEM Educ Train. 2017 May 12;1(3):221-224. doi: 10.1002/aet2.10037. eCollection 2017 Jul.

26.

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.

Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK.

Neuro Oncol. 2017 Oct 19;19(11):1481-1493. doi: 10.1093/neuonc/nox052.

27.

Measuring Kinase Activity-A Global Challenge.

Cann ML, McDonald IM, East MP, Johnson GL, Graves LM.

J Cell Biochem. 2017 Nov;118(11):3595-3606. doi: 10.1002/jcb.26103. Epub 2017 May 31. Review.

PMID:
28464261
28.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

29.

Landscaping a chromatin response to MEK inhibition.

Zawistowski JS, Goulet DR, Johnson GL.

Cell Cycle. 2017 Apr 18;16(8):731-732. doi: 10.1080/15384101.2017.1302232. Epub 2017 Mar 13. No abstract available.

30.

MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition.

Mobley RJ, Raghu D, Duke LD, Abell-Hart K, Zawistowski JS, Lutz K, Gomez SM, Roy S, Homayouni R, Johnson GL, Abell AN.

Cell Rep. 2017 Mar 7;18(10):2387-2400. doi: 10.1016/j.celrep.2017.02.030.

31.

Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.

Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves LM, Moorman NJ.

Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S263-S276. doi: 10.1074/mcp.M116.065375. Epub 2017 Feb 25.

32.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

33.

Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.

Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL, Kissil JL.

Oncotarget. 2016 Aug 23;7(34):54515-54525. doi: 10.18632/oncotarget.10248.

34.

Epigenetic inhibition of adaptive bypass responses to lapatinib by targeting BET Bromodomains.

Stuhlmiller TJ, Miller SM, Johnson GL.

Mol Cell Oncol. 2015 Jun 10;3(1):e1052182. doi: 10.1080/23723556.2015.1052182. eCollection 2016 Jan.

35.

Targeting the Breast Cancer Kinome.

Miller SM, Goulet DR, Johnson GL.

J Cell Physiol. 2017 Jan;232(1):53-60. doi: 10.1002/jcp.25427. Epub 2016 May 31. Review.

PMID:
27186656
36.

Weight loss reduces basal-like breast cancer through kinome reprogramming.

Qin Y, Sundaram S, Essaid L, Chen X, Miller SM, Yan F, Darr DB, Galanko JA, Montgomery SA, Major MB, Johnson GL, Troester MA, Makowski L.

Cancer Cell Int. 2016 Apr 1;16:26. doi: 10.1186/s12935-016-0300-y. eCollection 2016.

37.

Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.

Ahmad S, Johnson GL, Scott JE.

Biochem Biophys Res Commun. 2015 Aug 7;463(4):888-93. doi: 10.1016/j.bbrc.2015.06.029. Epub 2015 Jun 6.

38.

Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis.

Johnson GL, Sarker SJ, Nannini F, Ferrini A, Taylor E, Lass-Flörl C, Mutschlechner W, Bustin SA, Agrawal SG.

J Clin Microbiol. 2015 Jul;53(7):2103-8. doi: 10.1128/JCM.00110-15. Epub 2015 Apr 22.

39.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

40.
41.

Insufficient demonstration of long-term stability of Aspergillus galactomannan.

Johnson GL, Sarker SJ, Bustin SA, Agrawal SG.

J Clin Microbiol. 2014 Nov;52(11):4118. doi: 10.1128/JCM.02342-14. No abstract available.

42.

MEK inhibition in non-small cell lung cancer.

Stinchcombe TE, Johnson GL.

Lung Cancer. 2014 Nov;86(2):121-5. doi: 10.1016/j.lungcan.2014.09.005. Epub 2014 Sep 16. Review.

43.

Assessing adaptation of the cancer kinome in response to targeted therapies.

Zawistowski JS, Graves LM, Johnson GL.

Biochem Soc Trans. 2014 Aug;42(4):765-9. doi: 10.1042/BST20130274. Review.

44.

Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.

Tarpley M, Abdissa TT, Johnson GL, Scott JE.

Anticancer Res. 2014 Apr;34(4):1629-35.

45.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

46.

An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation.

Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW.

Mol Cell Proteomics. 2014 May;13(5):1184-97. doi: 10.1074/mcp.M113.037374. Epub 2014 Feb 20.

47.

Adaptive reprogramming of the breast cancer kinome.

Stuhlmiller TJ, Earp HS, Johnson GL.

Clin Pharmacol Ther. 2014 Apr;95(4):413-5. doi: 10.1038/clpt.2014.8. Epub 2014 Jan 10. Review.

48.

MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.

Pham TT, Angus SP, Johnson GL.

Genes Cancer. 2013 Nov;4(11-12):419-26. doi: 10.1177/1947601913513950.

49.

Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling.

Wu C, Haynes EM, Asokan SB, Simon JM, Sharpless NE, Baldwin AS, Davis IJ, Johnson GL, Bear JE.

J Cell Biol. 2013 Dec 23;203(6):907-16.

50.

UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS 3rd, Graham DK.

Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.

Supplemental Content

Loading ...
Support Center